var data={"title":"Cidofovir: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cidofovir: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin Rodriguez, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 17, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> was the first nucleotide analogue approved for clinical use. The drug has been employed almost exclusively to treat cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS). However, cidofovir is also used as a therapeutic option against other viral infections. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-aids-related-cytomegalovirus-retinitis\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> is a monophosphate nucleotide analogue. After undergoing cellular phosphorylation to its diphosphate form, it competitively inhibits the incorporation of deoxycytidine triphosphate into viral DNA by viral DNA polymerase. Incorporation of the drug disrupts further chain elongation [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Unlike nucleoside analogues such as <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> or <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>, cidofovir is not phosphorylated (and hence activated) by a viral kinase.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">SPECTRUM OF ACTIVITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> demonstrates in vitro activity against a number of DNA viruses, including the herpesviruses, adenovirus, polyomavirus, papillomavirus, and poxvirus [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/2\" class=\"abstract_t\">2</a>]. Cidofovir also retains activity against thymidine kinase-negative herpes simplex virus (HSV) and UL97 phosphotransferase-negative CMV, which are mutant viruses resistant to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> and <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>. Clinical efficacy has been demonstrated rigorously only against CMV. Its clinical utility in infections caused by other viral pathogens remains to be determined [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">MECHANISM OF RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reduced susceptibility of CMV to <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> has been associated with mutations in the viral DNA polymerase gene [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Since its mechanism of action does not require phosphorylation, cidofovir is unaffected by mutations in CMV phosphotransferase which confer resistance to <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>. However, prolonged therapy with ganciclovir in patients with CMV retinitis has been associated with the emergence of viral DNA polymerase mutations which confer cross resistance to cidofovir [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/4-8\" class=\"abstract_t\">4-8</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">BASIC PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Administration of a single dose of <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> (3 to 5 <span class=\"nowrap\">mg/kg</span> IV) yields peak plasma concentrations of 7.3 to 11.5 <span class=\"nowrap\">mg/L</span>. Over 80 percent of the drug is excreted unchanged in the urine within 24 hours, with a half-life of 2.4 to 3.2 hours [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. However, cidofovir diphosphate, an active metabolite is eliminated more slowly with first and second phase intracellular half-lives of 24 and 65 hours, respectively [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. This property permits the drug to be dosed every two weeks.</p><p>The most important toxicity of the drug is renal which can be reduced by coadministration with saline and <a href=\"topic.htm?path=probenecid-drug-information\" class=\"drug drug_general\">probenecid</a>; probenecid blocks active renal tubular secretion (see below). Dosing probenecid prior to, two hours after, and eight hours after <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> infusion may result in the doubling of serum concentrations [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. The fact that probenecid protects against nephrotoxicity and yet decreases renal clearance of the drug, may seem paradoxical. However, the drug appears to prevent damage to proximal renal tubular epithelial cells by preventing the uptake of cidofovir into these cells; at the same time, drug concentrations can decrease more slowly since these same renal cells are responsible for secreting the drug into the urine.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, the most important toxicity of <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> is dose dependent nephrotoxicity; the drug is contraindicated in persons with proteinuria (2+ or greater) or baseline serum creatinine greater than 1.5 <span class=\"nowrap\">mg/dL</span>. Cidofovir has been associated with decreased renal function and the emergence of a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9,10\" class=\"abstract_t\">9,10</a>]. Alternative formulations, such as brincidofovir (CMX001), an oral prodrug of cidofovir, may have less nephrotoxicity and is undergoing clinical studies [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/11\" class=\"abstract_t\">11</a>]. </p><p>To monitor for nephrotoxicity, serum creatinine and urine protein (dipstick is acceptable) should be checked within 48 hours prior to each dose of <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a>, and dose reduction or discontinuation is required for evidence of renal dysfunction. Approximately 50 percent of patients receiving cidofovir in clinical trials developed either proteinuria (2+ or greater), increased serum creatinine (rise of at least 0.4 <span class=\"nowrap\">mg/dL)</span> or decreased creatinine clearance (55 <span class=\"nowrap\">mL/min</span> or less) [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Renal dysfunction is usually reversible with discontinuation of the drug. However, a few cases of end-stage renal disease associated with the use of <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> in HIV-positive individuals have been reported [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Topical or intralesional use of cidofovir may also be rarely associated with renal dysfunction and monitoring may be necessary [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/14,15\" class=\"abstract_t\">14,15</a>]. The systemic absorption of cidofovir after topical application is probably higher if applied to non-intact skin.</p><p>Patients should receive one liter of normal saline over one to two hours immediately preceding the <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> dose and, if they can tolerate the fluid load, a second liter either during or immediately following the drug [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>]. Patients must also receive <a href=\"topic.htm?path=probenecid-drug-information\" class=\"drug drug_general\">probenecid</a> (2 g PO 3h prior and 1 g 2 and 8h following cidofovir) [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Nausea and vomiting are common side effects of <a href=\"topic.htm?path=probenecid-drug-information\" class=\"drug drug_general\">probenecid</a> and may be reduced by giving the drug with food or by administration of antiemetics. Rash is also common and management with an antihistamine <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a> may be appropriate [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Neutropenia has been observed in approximately 20 percent of patients receiving <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>]; it is more difficult to establish causality for this finding given its common appearance in advanced AIDS. In rats, cidofovir has been associated with mammary adenocarcinoma and thus it should be regarded as a potential human carcinogen [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Acute iritis and ocular hypotony, which have precluded intravitreal administration, have also been associated with intravenous <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/16,17\" class=\"abstract_t\">16,17</a>]. However, when evaluating a patient with ocular inflammation who is receiving both cidofovir for CMV retinitis and highly active antiretroviral therapy (HAART) one must also consider the possibility of vitritis associated with immune system recovery.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">USE IN PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> has been assigned to Pregnancy Category C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table graphicRef50021 \">table 1</a>). It is embryotoxic in rats and rabbits, and there are no adequate studies in pregnant women. Women of childbearing potential should use contraception during and for one month following treatment with cidofovir, and men who have sex with women of childbearing potential should use barrier contraception during and for three months after treatment [<a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/9\" class=\"abstract_t\">9</a>].</p><p><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> should be used in pregnant women only if the potential benefits outweigh the risk to the fetus.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">CLINICAL USE OF CIDOFOVIR</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> has only been rigorously studied in AIDS patients for treatment of CMV retinitis. The management of AIDS patients with CMV retinitis is discussed elsewhere. </p><p>Guidance on the use of <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> for other potential indications is found elsewhere. (See <a href=\"topic.htm?path=monkeypox#H3087553\" class=\"medical medical_review\">&quot;Monkeypox&quot;, section on 'Cidofovir'</a> and <a href=\"topic.htm?path=diagnosis-treatment-and-prevention-of-adenovirus-infection#H18\" class=\"medical medical_review\">&quot;Diagnosis, treatment, and prevention of adenovirus infection&quot;, section on 'Cidofovir'</a> and <a href=\"topic.htm?path=treatment-of-drug-resistant-genital-herpes-simplex-virus-infection-in-hiv-infected-patients#H28740855\" class=\"medical medical_review\">&quot;Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients&quot;, section on 'Topical therapies'</a> and <a href=\"topic.htm?path=human-herpesvirus-6-infection-in-hematopoietic-cell-transplant-recipients#H665911113\" class=\"medical medical_review\">&quot;Human herpesvirus 6 infection in hematopoietic cell transplant recipients&quot;, section on 'Antiviral therapy'</a> and <a href=\"topic.htm?path=prevention-and-management-of-bk-virus-induced-polyomavirus-induced-nephropathy-in-kidney-transplantation#H13\" class=\"medical medical_review\">&quot;Prevention and management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation&quot;, section on 'Cidofovir'</a> and <a href=\"topic.htm?path=common-causes-of-hoarseness-in-children#H36\" class=\"medical medical_review\">&quot;Common causes of hoarseness in children&quot;, section on 'Papillomatosis (HPV)'</a> and <a href=\"topic.htm?path=vaccinia-virus-as-the-smallpox-vaccine#H2169907457\" class=\"medical medical_review\">&quot;Vaccinia virus as the smallpox vaccine&quot;, section on 'Experimental agents'</a>.)</p><p class=\"headingAnchor\" id=\"H1177297\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> is a monophosphate nucleotide analogue of deoxycytidine (dCTP). After undergoing cellular phosphorylation, cidofovir competitively inhibits the incorporation of dCTP into viral DNA by viral DNA polymerase. Incorporation of the drug disrupts further chain elongation. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> demonstrates in vitro activity against a number of DNA viruses, including adenovirus, polyomavirus, papillomavirus, poxvirus and the herpesviruses (including acyclovir-resistant strains of HSV). Clinical efficacy has been demonstrated rigorously only against cytomegalovirus infection. (See <a href=\"#H3\" class=\"local\">'Spectrum of activity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced susceptibility of cytomegalovirus to <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> has been associated with mutations in the viral DNA polymerase gene. (See <a href=\"#H4\" class=\"local\">'Mechanism of resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Over 80 percent of <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> is excreted unchanged in the urine within 24 hours, with a half-life of 2.4 to 3.2 hours. However, its active metabolite is eliminated more slowly, which permits drug dosing every two weeks. (See <a href=\"#H5\" class=\"local\">'Basic pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most important toxicity of <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> is dose-dependent nephrotoxicity; cidofovir has been associated with decreased renal function and the emergence of a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting. Cidofovir is contraindicated in persons with significant proteinuria or with a baseline serum creatinine greater than 1.5 <span class=\"nowrap\">mg/dL</span>. (See <a href=\"#H6\" class=\"local\">'Toxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients should receive one liter of normal saline over one to two hours immediately preceding <a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">cidofovir</a> dosing. If they can tolerate the fluid load, a second liter should be given either during or immediately following cidofovir administration. Patients must also receive <a href=\"topic.htm?path=probenecid-drug-information\" class=\"drug drug_general\">probenecid</a> (2 g PO 3 hours prior and 1 g 2 and 8 hours following cidofovir), which may prevent damage to proximal renal tubular epithelial cells by preventing the uptake of cidofovir into these cells. (See <a href=\"#H6\" class=\"local\">'Toxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> should be used in pregnant women only if the potential benefits outweigh the risk to the fetus. (See <a href=\"#H7\" class=\"local\">'Use in pregnancy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/1\" class=\"nounderline abstract_t\">Lea AP, Bryson HM. Cidofovir. Drugs 1996; 52:225.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/2\" class=\"nounderline abstract_t\">De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/3\" class=\"nounderline abstract_t\">Cherrington JM, Fuller MD, Lamy PD, et al. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J Infect Dis 1998; 178:1821.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/4\" class=\"nounderline abstract_t\">Erice A, Gil-Roda C, P&eacute;rez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/5\" class=\"nounderline abstract_t\">Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176:786.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/6\" class=\"nounderline abstract_t\">Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/7\" class=\"nounderline abstract_t\">Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/8\" class=\"nounderline abstract_t\">Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010; 50:733.</a></li><li class=\"breakAll\">VISTIDE prescribing information. Gilead Sciences, Inc., 1996.</li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/10\" class=\"nounderline abstract_t\">Vittecoq D, Dumitrescu L, Beaufils H, Deray G. Fanconi syndrome associated with cidofovir therapy. Antimicrob Agents Chemother 1997; 41:1846.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/11\" class=\"nounderline abstract_t\">Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369:1227.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/12\" class=\"nounderline abstract_t\">Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29:948.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/13\" class=\"nounderline abstract_t\">Meier P, Dautheville-Guibal S, Ronco PM, Rossert J. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17:148.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/14\" class=\"nounderline abstract_t\">Naiman AN, Roger G, Gagnieu MC, et al. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 2004; 114:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/15\" class=\"nounderline abstract_t\">Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002; 73:661.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/16\" class=\"nounderline abstract_t\">Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733.</a></li><li><a href=\"https://www.uptodate.com/contents/cidofovir-an-overview/abstract/17\" class=\"nounderline abstract_t\">Friedberg DN. Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:801.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8297 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1177297\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">SPECTRUM OF ACTIVITY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">MECHANISM OF RESISTANCE</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">BASIC PHARMACOKINETICS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">TOXICITY</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">USE IN PREGNANCY</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">CLINICAL USE OF CIDOFOVIR</a></li><li><a href=\"#H1177297\" id=\"outline-link-H1177297\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8297|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/50021\" class=\"graphic graphic_table\">- Drug ratings in pregnancy (US Food and Drug Administration)</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=common-causes-of-hoarseness-in-children\" class=\"medical medical_review\">Common causes of hoarseness in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-treatment-and-prevention-of-adenovirus-infection\" class=\"medical medical_review\">Diagnosis, treatment, and prevention of adenovirus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=human-herpesvirus-6-infection-in-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">Human herpesvirus 6 infection in hematopoietic cell transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=monkeypox\" class=\"medical medical_review\">Monkeypox</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-aids-related-cytomegalovirus-retinitis\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-management-of-bk-virus-induced-polyomavirus-induced-nephropathy-in-kidney-transplantation\" class=\"medical medical_review\">Prevention and management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-genital-herpes-simplex-virus-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccinia-virus-as-the-smallpox-vaccine\" class=\"medical medical_review\">Vaccinia virus as the smallpox vaccine</a></li></ul></div></div>","javascript":null}